ArticleRadiation oncology journal2018
Natural radioprotectors and their impact on cancer drug discovery.
Article in Radiation oncology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 59 citations in OpenAlex.
- Effectiveness of oral famotidine in reducing the hematologic complications of radiotherapy in patients with esophageal and cardia cancers: a randomized controlled trial.Radiation oncology (London, England) · 2023Trial
- Breaking through the radiation dilemma: development and clinical translation of anti-radiation drugs.Pharmaceutical science advances · 2026Review
- Radiosensitizing effects of Withaferin A in gastric cancer cells via autophagy Inhibition and mitochondrial disruption.Scientific reports · 2025Article
- Neuroprotective Action of Selected Natural Drugs Against Neurological Diseases and Mental Disorders: Potential Use Against Radiation Damage.Neurochemical research · 2024Review
- Article
- Crosstalk between Oxidative Stress and Inflammation Induced by Ionizing Radiation in Healthy and Cancerous Cells.Current medicinal chemistry · 2024Review
- Radioprotective Potency of Nanoceria.Current radiopharmaceuticals · 2024Review
- Connection between Radiation-Regulating Functions of Natural Products and miRNAs Targeting Radiomodulation and Exosome Biogenesis.International journal of molecular sciences · 2023Review
- Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer.Cancers · 2023Review
- Effect of curcumin on γ-ray-induced cell response.Journal of radiation research · 2023Article
- Radioprotective Effect of Thymoquinone in X-irradiated Rats.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Cytotoxicity and radiosensitizing potency of Moscatilin in cancer cells at low radiation doses of X-ray and UV-C.3 Biotech · 2021Article
- Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition.Medical oncology (Northwood, London, England) · 2021Review
- Radioprotective potential of <italic>Costus afer</italic> against the radiation-induced hematological and histopathological damage in mice.Radiation oncology journal · 2021Article
- Roles of Therapeutic Bioactive Compounds in Hepatocellular Carcinoma.Oxidative medicine and cellular longevity · 2021Review
- Reflectance structured illumination imaging of internalized cerium oxide nanoparticles modulating dose-dependent reactive oxygen species in breast cancer cells.Biochemistry and biophysics reports · 2020Article
- Assessment of monoamine neurotransmitters in the cortex and cerebellum of gamma-irradiated mice: A neuromodulatory role ofJournal of carcinogenesis · 2020Article
- Impact of bladder volume on treatment planning and clinical outcomes of radiotherapy for patients with cervical cancer.Cancer management and research · 2019Article
- Natural Radioprotectors on Current and Future Perspectives: A Mini-Review.Journal of pharmacy & bioallied sciencesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancer is a complex multifaceted illness that affects different patients in discrete ways. For a number of cancers the use of chemotherapy has become standard practice. Chemotherapy is a use of cytostatic drugs to cure cancer. Cytostatic agents not only affect cancer cells but also affect the growth of normal cells; leading to side effects. Because of this, radiotherapy gained importance in treating cancer. Slaughtering of cancerous cells by radiotherapy depends on the radiosensitivity of the tumor cells. Efforts to improve the therapeutic ratio have resulted in the development of compounds that increase the radiosensitivity of tumor cells or protect the normal cells from the effects of radiation. Amifostine is the only chemical radioprotector approved by the US Food and Drug Administration (FDA), but due to its side effect and toxicity, use of this compound was also failed. Hence the use of herbal radioprotectors bearing pharmacological properties is concentrated due to their low toxicity and efficacy. Notably, in silico methods can expedite drug discovery process, to lessen the compounds with unfavorable pharmacological properties at an early stage of drug development. Hence a detailed perspective of these properties, in accordance with their prediction and measurement, are pivotal for a successful identification of radioprotectors by drug discovery process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.